Ip Dividends - IPO

Ip Dividends - IPO

[ADVERT]
Best deals to access real time data!
Level 2 Basic
Monthly Subscription
for only
£62.08
Silver
Monthly Subscription
for only
£17.37
UK/US Silver
Monthly Subscription
for only
£30.59
VAT not included
Stock Name Stock Symbol Market Stock Type
Ip Group Plc IPO London Ordinary Share
  Price Change Price Change % Stock Price Last Trade
-1.00 -0.77% 128.20 16:35:29
Open Price Low Price High Price Close Price Previous Close
129.60 127.60 129.60 128.20 129.20
more quote information »
Industry Sector
GENERAL FINANCIAL

Ip IPO Dividends History

Announcement Date Type Currency Dividend Amount Period Start Period End Ex Date Record Date Payment Date Total Dividend Amount
05/08/2021InterimGBX130/12/202030/06/202112/08/202113/08/202127/09/20210

Top Dividend Posts

DateSubject
15/10/2021
11:52
p1nkfish: I'm still of the opinion IPO need all the cash they can get their hands on to support their investments in what may be a winter period. Post that period, in the right investments, it will be winner takes all and positioning for that will be critical. In Energy & Health in particular where new deep tech could run off with very special prizes. If you hear what Macron is saying in France, UK need to be ready to compete. Modular Nuclear (Fusion ideally) and Green H2 - winner takes all. Was part of his France 2030 speech/vision. We need to be ready to fight to win with the likes of IPO tooled up to support British and Anglosphere companies. Yes, I am very pro-Britain. This is no time to let cash out except into future growth for the UK imho. That's what IPO is for, we will benefit with capital appreciation.
03/10/2021
14:18
p1nkfish: Keyno, no future guaranteed0p but IPO's target is growth. VOD is fundamentally x-growth in a commoditised market. IPOs market is decidedly not commoditised. The results of buybacks will be dissimilar. Personally, I would prefer IPO to invest in new opportunities but the number of qualifying opps needed to allocate the available capital may be too high unless some need substantial cash. Quality needs to come before quantity and excess funds then allocated to the next level. If IPO realistically expect portfolio growth there may be nothing better than their own stock. Another consideration is portfolio size. These companies need some guidance and beyond a certain number management is spread too thin, amongst too many. If they are to return some cash I would prefer buybacks and as it can help future eps growth it could encourage some to hold for longer. If you want a dividend income stream then VOD, BP etc are a better home.
01/10/2021
10:53
p1nkfish: Hard to predict much with a timeliness. I stick to £2 but very loose timing. Depends on the number of speculative holders in IPO and ONT and the state of the market in next 6 months or so. Worse case is a bad market shake where ONT weakens and some sell IPO. IPO then gets a double whammy on money flow and NAV. I hold a lot of these so I'm not talking it down, just thinking worse case scenario through.
30/9/2021
08:01
bamboo2: IP Group PLC IP Group generates GBP84m from Oxford Nanopore IPO IP Group plc - Portfolio company Oxford Nanopore priced at GBP3.4billion, IP Group generates GBP84m of proceeds*; retains holding valued at GBP348.8m IP Group plc (LSE: IPO) ("IP Group" or "the Group"), the developer of intellectual property-based businesses, notes that portfolio company Oxford Nanopore Technologies plc ("Oxford Nanopore" or "the Company"), the Company behind a new generation of nanopore-based sensing technology, whose products enable the real-time, high-performance, scalable analysis of DNA and RNA, has announced the successful pricing of its initial public offering (the "IPO" or the "Offer") at 425 pence per Share (the "Offer Price"). The Company's market capitalisation will be approximately GBP3.4 billion at the commencement of conditional dealings on the main market of the London Stock Exchange. Oxford Nanopore noted that, following positive feedback from potential investors, it now intends to issue approximately 82.4 million new Shares raising gross process of approximately GBP350 million. The Offer also comprises approximately 41 million existing Shares to be sold by certain existing shareholders, equating to a total Offer size of c.GBP524 million. An additional c.18.5 million new Shares are being made available by the Company pursuant to the over-allotment option. IP Group announces that it has realised approximately GBP84m of proceeds* through the partial sale of its holding in Oxford Nanopore. Consistent with the Group's Capital Allocation Policy, the Board is allocating GBP15m of this realisation towards buybacks of its own shares, with the balance to be invested into opportunities within the Group's existing business. Including the GBP20m announced earlier this year, none of which has been utilised to date, a total of GBP35m is now reserved for buybacks. The buyback programme remains subject to various factors including our shareholder authorities to only buy back shares at a discount to Hard NAV per share. Decisions to repurchase shares will always be undertaken in conjunction with considering other potential investment opportunities for the benefit of stakeholders. The Group will update shareholders on the utilisation of this capital via the relevant regulatory announcements. Following the sale, IP Group holds 82,062,144 shares (or 10.3% of Oxford Nanopore) which is valued at GBP 348.8 million based on the GBP4.25 Offer Price of Oxford Nanopore. This represents a realised and unrealised fair value gain to IP Group of approximately GBP74m*. Alan Aubrey, Chief Executive of IP Group , said: " We're delighted to see such continued strong global interest in and support for Oxford Nanopore. Since IP Group helped found Oxford Nanopore in 2005, the Company has gone from strength to strength. It is a great example of how IP Group has helped nurture a world-leading company based on scientific research and we're immensely proud of the team's achievements." Conditional dealings in the Shares are expected to commence on the London Stock Exchange at 08:00 am (UK time) on 30 September 2021 under the ticker "ONT". Admission of the Shares is expected to occur, and unconditional dealings in the Shares are expected to commence on the London Stock Exchange, at 08:00 am (UK time) on 5 October 2021. The person responsible for arranging the release of this announcement on behalf of the Company is Alan Aubrey, Chief Executive of IP Group. *net of estimated costs
11/9/2021
10:15
pierre oreilly: Alan was appointed as a Non-Executive Director in March 2009. Alan has informed the Board that should any potential IPO occur, he intends to retire from the Board and his position as chair of the audit and risk committee at the date of such IPO. .................... The above from the nano float documents. I think we can assume from that (might be wrong of course) that ipo are liquidating most of their holding in the float. Elsewhere, it's interesting that ipo was the initial seed capital investor in nano enabling it to launch.
05/8/2021
07:44
bamboo2: FOR RELEASE ON 05 August 2021 ("IP Group" or "the Group" or "the Company") Half-yearly results Strong return, significant cash realisations, capital recycled for growth alongside interim dividend and share buyback IP Group plc (LSE: IPO), the developer of intellectual property-based businesses, today announces its financial results for the six months ended 30 June 2021. Half-year highlights -- Strong Return on Hard NAV[1] of GBP117.9m, or 9%, (HY20: GBP14.2m; FY20: GBP189.5m) -- Hard NAV[2] of GBP1,439.3m or 135.4 pence per share (HY20: GBP1,156.4m or 108.8pps; FY20: GBP1,331.5m or 125.3pps) -- Cash realisations of GBP111.4m (HY20: GBP113.7m; FY20: GBP191.0m) -- Sustained investment into portfolio: GBP69.5m into 41 companies (HY20 GBP36.9m; FY20: GBP67.5m) -- Interim dividend of 0.48p per share and GBP20m allocated to buying back the Group's shares Portfolio highlights -- Fair value of portfolio: GBP1,246.4m (HY20: GBP1,025.0m; FY20: GBP1,162.7m) -- Net portfolio gains of GBP143.1m (HY20: GBP34.9m; FY20: GBP231.4m) -- Sales of Inivata Ltd to NeoGenomics, Inc, WaveOptics Ltd to Snap, Inc and Kuur Therapeutics Ltd to Athenex, Inc. -- Oxford Nanopore announced it has begun preparations for a potential IPO -- Total funds raised by portfolio companies: Approximately GBP1.0bn (HY20 GBP365m; FY20: GBP1.1bn) including Oxford Nanopore Technologies Ltd (GBP202m), Centessa Pharmaceuticals Ltd (US$630m/GBP457m), Pulmocide Ltd (US$92m/GBP67m committed, US$25m/GBP18m invested) and MOBILion (US$60m/GBP43m)[3] Other financial and operational highlights -- Net assets GBP1,439.7m (HY20: GBP1,156.8m; FY20: GBP1,331.9m) -- Profit of GBP116.5m (HY20: GBP11.7m; FY20: GBP185.4m) -- Strong liquidity with gross cash and deposits at 30 June 2021 of GBP308.9m (HY20: GBP245.3m; FY20: GBP270.3m) and Net Cash[4] of GBP249.4m (HY20: GBP170.5m; FY20: GBP203.0m) -- North American platform, IP Group, Inc secured additional funding, bringing total raised in H1 to US$59m (GBP43m(3) ) -- Joint venture formed with China Everbright Ltd to launch first third-party fund in China Alan Aubrey, Chief Executive of IP Group, said: "IP Group has continued to make strong headway in 2021 with much activity in the portfolio. Three companies have been sold for significant returns, one company has floated on Nasdaq and Oxford Nanopore Technologies, our largest holding, has confirmed it is planning an IPO in the second half of the year. The Group has delivered strong financial performance in the first half with a Return on Hard NAV of 9% and cash realisations of GBP111.4m. As a result, we are following our maiden full year 2020 dividend with an interim dividend and have allocated GBP20m of our capital to commence a buyback of the Group's shares. I am delighted to report that the company is in a strong financial position with Net Cash of GBP249.4m. This financial strength provides important flexibility in the face of uncertainty caused by the ongoing COVID-19 pandemic and enables us to support our portfolio with scale-up capital alongside co-investors. We continue to be excited by the prospects for the second half of the year including the opportunities our portfolio businesses have from the renewed focus on innovation and sustainability." Webinar IP Group will host a webinar for analysts and investors today, 10:00 GMT.
09/6/2021
07:40
bamboo2: Good news, particularly about the buyback. Webinar at 10.15am today. These are normally worthwhile, with a live Q&A. If you want to submit a question during this time, it is worth preparing in advance what you want to say in another text editor, then paste it to Zoom's small text box. =============================================================== IP Group plc - AGM statement IP Group plc (LSE: IPO) ("IP Group" or "the Company" or "the Group"), the developer of intellectual property-based businesses, issues the following statement ahead of its Annual General Meeting, which is a closed meeting taking place at 10am today and which will be followed by a virtual event for shareholders at 10.15am . All shareholders are invited to join the virtual event at 10.15am while we politely remind shareholders that the 2021 AGM is a closed meeting with the minimum attendance required to form a quorum (being two shareholders). No other shareholders will be permitted to physically attend the meeting in accordance with the UK Government's current COVID-19 guidelines and to safeguard shareholders, employees and the wider community. No material new information will be released by the Company during the virtual event. This statement provides an update on the Group's progress for the period since 31 December 2020. Business and operational update During the year to date, IP Group has seen a continuation of the positive progress made by many of its portfolio companies during 2020. A summary of significant portfolio events is set out below. The Group remains well financed and, as at 31 May 2021, had gross cash and deposits of GBP228.7 million (FY20: GBP270.3 million) and net cash (gross cash and deposits less EIB debt) of GBP169.1 million (FY20: GBP203.0 million) Shareholder returns and inaugural dividend As described in the 2020 full year results release, the Board considers that IP Group shareholder returns will continue to be driven primarily by long-term capital appreciation. The Board also considers that the business model has reached a sufficient stage of maturity that a modest but growing dividend should form a small part of the overall shareholder value proposition. Consistent with this approach, and assuming approval of the relevant resolutions at the Group's AGM later today, the Group will pay its inaugural dividend of one pence per ordinary share on 16(th) June. GBP10.1 million of the dividend will be settled in cash and GBP0.5m via the issue of new ordinary shares under the Group's scrip programme. The Board also anticipates receiving shareholder approval to renew the authority to purchase up to 10% of the ordinary shares in issue from the date of grant of the authority to the date of the Annual General Meeting in 2022. Such purchases will only be made at a discount to the prevailing Hard NAV per share. Any decision to repurchase shares would be undertaken in light of other potential capital investment opportunities for the benefit of stakeholders and remains subject to regular review. Portfolio update The Group's portfolio includes holdings in 40 'focus' companies across life sciences, deeptech and cleantech, representing over 84% of the portfolio value at 31 December 2020. In the year to date, the Group has invested over GBP50 million in 32 portfolio companies and made cash realisations of GBP16 million. The Directors anticipate that cash realisations in the first half of the year will exceed GBP80 million following the completion of certain portfolio transactions described below. Management is currently undertaking its regular fair value assessment exercise as part of its half-yearly results processes and looks forward to updating shareholders in August. Significant developments in the Group's portfolio since 31 December 2020 include: -- NeoGenomics, Inc agreed to acquire Inivata Ltd, a leader in liquid biopsy, resulting in IP Group receiving approximately GBP65 million* ($91 million) in cash and an anticipated increase in the Group's net asset value of approximately GBP28 million. -- Waveoptics Ltd was sold to Snap Inc, in one of Europe's largest deeptech exits, as announced on 17 May. Following completion, IP Group has recorded a fair value increase of approximately GBP20 million. -- Oxford Nanopore Technologies Ltd raised GBP202 million in new capital including GBP125 million from new investors Temasek, Wellington Management, M&G Investments and Nikon with existing shareholders investing GBP77 million. Following completion of the round, IP Group has a 14.5% undiluted beneficial stake in Oxford Nanopore, valued at GBP359 million. Oxford Nanopore announced in March that it had started the process of preparing for a potential Initial Public Offering. -- Kuur Therapeutics Ltd was acquired by Athenex, Inc. for a total potential consideration of $185 million with IP Group eligible to receive GBP30 million* ($42 million) in Athenex stock and up to a further GBP51 million* ($72 million) in milestone payments in cash or stock. The Directors anticipate that the transaction will result in an increase in the Group's net asset value of approximately GBP26 million*. -- Centessa Pharmaceuticals plc announced that its Nasdaq IPO had closed on 2 June 2021 and its American Depositary Shares were now trading under the symbol 'CNTA'. IP Group had previously announced that portfolio company Apcintex Ltd had been acquired by Centessa. Based on the IPO price of $20 per share, the value of the Group's 2.8% holding in Centessa was GBP36 million* ($51 million) , resulting in an increase in the Group's net asset value of GBP15 million. Centessa noted that gross proceeds from the offering totalled $379.5 million. -- Diurnal Group plc announced on May 28 that the European Commission (EC) had approved the marketing authorisation for Efmody(R) (hydrocortisone modified-release hard capsules, development name Chronocort(R) ) as treatment of adult and adolescent patients (12 years and older) with the rare condition congenital adrenal hyperplasia (CAH). This decision by the EC follows the positive opinion issued by the European Medicines Agency (EMA) in March 2021. First commercial launch is anticipated in Q3 2021. -- Pulmocide Ltd completed a $92 million Series C financing. Following completion and the investment of the first tranche of GBP2.2 million, IP Group will have a 14.4% undiluted beneficial stake in Pulmocide, which will be valued at GBP8.0 million.
09/6/2021
07:07
masurenguy: Good update and dividend inaugurated ! Business and operational update During the year to date, IP Group has seen a continuation of the positive progress made by many of its portfolio companies during 2020. The Group remains well financed and, as at 31 May 2021, had gross cash and deposits of £228.7 million (FY20: £270.3 million) and net cash (gross cash and deposits less EIB debt) of £169.1 million (FY20: £203.0 million) Shareholder returns and inaugural dividend As described in the 2020 full year results release, the Board considers that IP Group shareholder returns will continue to be driven primarily by long-term capital appreciation. The Board also considers that the business model has reached a sufficient stage of maturity that a modest but growing dividend should form a small part of the overall shareholder value proposition. Consistent with this approach, and assuming approval of the relevant resolutions at the Group's AGM later today, the Group will pay its inaugural dividend of one pence per ordinary share on 16(th) June. GBP10.1 million of the dividend will be settled in cash and GBP0.5m via the issue of new ordinary shares under the Group's scrip programme. The Board also anticipates receiving shareholder approval to renew the authority to purchase up to 10% of the ordinary shares in issue from the date of grant of the authority to the date of the Annual General Meeting in 2022. Such purchases will only be made at a discount to the prevailing Hard NAV per share. Any decision to repurchase shares would be undertaken in light of other potential capital investment opportunities for the benefit of stakeholders and remains subject to regular review. https://uk.advfn.com/stock-market/london/ip-IPO/share-news/IP-Group-PLC-AGM-Statement/85315167
20/5/2021
16:07
bamboo2: FOR RELEASE ON 20 May 2021 IP Group plc Scrip Dividend Reference Price Further to the Company's Annual Results Release on 10 March 2021 and the 2021 AGM Notice which was published on 6 May 2021, the Company announces that the Scrip Reference Share Price for the 2020 Final Dividend, payable on 16 June 2021, is 118.6 pence. Defined terms in this announcement are as defined in the 2021 AGM Notice. The Scrip Reference Share Price is the price at which the Company's Ordinary Shares will be issued to shareholders who have elected to receive dividends in the form of newly issued, fully paid shares in the Company in lieu of cash through participation in the optional Scrip Dividend Scheme. The Scrip Reference Share Price is the average of the mid closing price of the Company's Ordinary Shares, as derived from the London Stock Exchange Daily Official List, for the five dealing days commencing on the relevant ex-dividend date (being 13, 14, 17, 18 and 19 May 2021). Any shareholder entitled to the 2020 Final Dividend who has not already completed a Scrip Dividend Mandate Form or a Dividend Election Input Message in CREST and is intending to do so, should refer to the Scrip Dividend Scheme Terms and Conditions contained within the 2021 AGM Notice which can be found at: hxxps://www.ipgroupplc.com/investor-relations/shareholder-information/agm . The final time and date for receipt of Scrip Dividend Mandates and Dividend Election Input Messages in CREST is 5:00pm on 28 May 2021.
06/5/2021
19:12
bamboo2: IP Group plc - 2020 Annual Report; Notice of AGM; Scrip Dividend Scheme IP Group plc (LSE: IPO) ("IP Group" or "the Company" or "the Group"), the developer of intellectual property-based businesses, announces that it has published its Annual Report and Accounts for the year ended 31 December 2020. In compliance with Listing Rule 9.6.3, a copy of the following documents will shortly be available for inspection at www.fca.org.uk/markets/primary-markets/regulatory-disclosures/national-storage-mechanism . - Annual Report and Accounts for the year ended 31 December 2020 ("2020 ARA"); and - Notice of 2021 Annual General Meeting ("2021 AGM Notice") containing the terms and conditions of the Scrip Dividend Scheme, including the scrip dividend in respect of the 2020 final dividend ("Scrip Dividend Scheme Terms and Conditions"). Printed copies of these documents together with the Form of Proxy for use in connection with the 2021 Annual General Meeting and a Scrip Dividend Mandate Form have been posted to shareholders who have requested hard copies. An electronic copy of the 2020 ARA is available on the Investor Relations section of the IP Group website at www.ipgroupplc.com/investor-relations . Copies of the 2021 AGM Notice incorporating the Scrip Dividend Scheme Terms and Conditions, the Scrip Dividend Mandate Form and the changes to the Company's articles of association proposed for approval at the 2021 AGM are also available electronically on the IP Group website at Https://www.ipgroupplc.com/investor-relations/shareholder-information/agm . The 2021 Annual General Meeting will be held at 10.00am on 09 June 2020 at the Company's offices at The Walbrook Building, 25 Walbrook, London, EC4N 8AF. Given the UK Government's current COVID-19 guidelines, the Board has taken the decision to hold the 2021 AGM as a closed meeting with the minimum attendance required to form a quorum (being two shareholders). No other shareholders will be permitted to physically attend the meeting. The Company requests that shareholders submit their votes by proxy either electronically or by post, in accordance with the instructions in the 2021 AGM Notice. The Company is taking these precautionary measures to safeguard its shareholders' and employees' health and make the AGM as safe and efficient as possible. The Board greatly values the opportunity to meet its shareholders and as such we currently intend to hold a webinar immediately after the AGM at which a Group update will be provided and shareholders will be able to ask questions of the Board, both in advance and live on the day. Details of the time of the webinar and how to access it will be made available on the Group's website nearer the date of the AGM at www.ipgroupplc.com/investor-relations/shareholder-information/agm . The Board will keep these AGM arrangements under review and the Board will update shareholders via the Regulatory News Service ("RNS") as appropriate, with any such announcements also uploaded to the Company's website ( Https://www.ipgroupplc.com/investor-relations/shareholder-information/agm ) . The Company encourages shareholders to check its website regularly for the latest information on the arrangements for the AGM.
ADVFN Advertorial
Your Recent History
LSE
IPO
Ip
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20211019 00:18:54